BioCryst Pharmaceuticals, Inc. (BCRX)

5.27 +0.82 (+18.43%) 收市：04:00PM EDT

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302
https://www.biocryst.com

版塊: Healthcare
行業: Biotechnology
全職員工: 536

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Jon P. Stonehouse	CEO, President & Executive Director	1.23M	647.14k	1961
Mr. Anthony J. Doyle	Senior VP, CFO & Interim Principal Accounting Officer	845.93k	無	1980
Ms. Alane P. Barnes	Senior VP, Chief Legal Officer & Corporate Secretary	794.75k	無	1966
Dr. Helen M. Thackray FAAP, M.D.	Chief Research & Development Officer	976.15k	無	1968
Mr. Charles K. Gayer	Senior VP & Chief Commercial Officer	794.12k	無	1971
Mr. John D. Bluth	Chief Communications Officer	無	無	1973
Ms. Stephanie Angelini	Chief People Officer	無	無	無
Dr. William P. Sheridan MBBS	Chief Development Officer	784.09k	4.4M	1955
Dr. Yarlagadda S. Babu Ph.D.	Chief Discovery Officer	691.45k	1.25M	1953
Ms. Jinky Ang Rosselli	Chief Data & Insights Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

公司管治

截至 2024年5月1日 止，BioCryst Pharmaceuticals, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：8；董事會：3；股東權利：8；現金賠償：5。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。